Hualan Biological EngineeringInc Total Liabilities
Hualan Biological EngineeringInc total liabilities. Based on the latest financial reports, Hualan Biological EngineeringInc (002007) has total liabilities worth CN¥3.02 Billion CNY (≈ $441.59 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Hualan Biological EngineeringInc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Hualan Biological EngineeringInc (2001–2024)
Total liabilities of Hualan Biological EngineeringInc from 2001 to 2024. This chart illustrates how Hualan Biological EngineeringInc's total liabilities have evolved over time, based on quarterly financial data. Explore Hualan Biological EngineeringInc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Hualan Biological EngineeringInc Competitors by Total Liabilities
The table below lists competitors of Hualan Biological EngineeringInc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Galaxy Securities Co Ltd
F:CGL
|
Germany | €707.95 Billion |
|
China Minsheng Banking Corp. Ltd
F:GHFH
|
Germany | €7.13 Trillion |
|
Impinj Inc
NASDAQ:PI
|
USA | $335.95 Million |
|
Genscript Biotech Corporation
F:G51
|
Germany | €888.59 Million |
|
Ninestar Corp
SHE:002180
|
China | CN¥7.51 Billion |
|
DOF Group ASA
OL:DOFG
|
Norway | Nkr2.17 Billion |
|
FIT Hon Teng Limited
F:0FJ
|
Germany | €3.18 Billion |
|
Gentera S.A.B. de C.V
MX:GENTERA
|
Mexico | MX$84.73 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Hualan Biological EngineeringInc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 002007 asset base.
Liquidity & Leverage Metrics
Hualan Biological EngineeringInc Total Liabilities Ratios Explained
Hualan Biological EngineeringInc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hualan Biological EngineeringInc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hualan Biological EngineeringInc (2001–2024)
The table below shows the annual total liabilities of Hualan Biological EngineeringInc from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥2.46 Billion ≈ $360.45 Million |
-8.25% |
| 2023-12-31 | CN¥2.68 Billion ≈ $392.84 Million |
+6.09% |
| 2022-12-31 | CN¥2.53 Billion ≈ $370.27 Million |
+2.31% |
| 2021-12-31 | CN¥2.47 Billion ≈ $361.91 Million |
+27.60% |
| 2020-12-31 | CN¥1.94 Billion ≈ $283.62 Million |
+177.18% |
| 2019-12-31 | CN¥699.26 Million ≈ $102.32 Million |
-2.94% |
| 2018-12-31 | CN¥720.47 Million ≈ $105.43 Million |
+90.98% |
| 2017-12-31 | CN¥377.24 Million ≈ $55.20 Million |
+75.42% |
| 2016-12-31 | CN¥215.05 Million ≈ $31.47 Million |
+56.85% |
| 2015-12-31 | CN¥137.11 Million ≈ $20.06 Million |
+2.55% |
| 2014-12-31 | CN¥133.70 Million ≈ $19.56 Million |
-59.80% |
| 2013-12-31 | CN¥332.55 Million ≈ $48.66 Million |
+152.24% |
| 2012-12-31 | CN¥131.84 Million ≈ $19.29 Million |
-14.38% |
| 2011-12-31 | CN¥153.99 Million ≈ $22.53 Million |
-9.45% |
| 2010-12-31 | CN¥170.06 Million ≈ $24.89 Million |
+9.25% |
| 2009-12-31 | CN¥155.67 Million ≈ $22.78 Million |
+32.49% |
| 2008-12-31 | CN¥117.50 Million ≈ $17.19 Million |
-59.28% |
| 2007-12-31 | CN¥288.51 Million ≈ $42.22 Million |
+26.73% |
| 2006-12-31 | CN¥227.67 Million ≈ $33.31 Million |
+52.60% |
| 2005-12-31 | CN¥149.20 Million ≈ $21.83 Million |
+3.94% |
| 2004-12-31 | CN¥143.53 Million ≈ $21.00 Million |
-34.40% |
| 2003-12-31 | CN¥218.79 Million ≈ $32.02 Million |
+48.36% |
| 2002-12-31 | CN¥147.47 Million ≈ $21.58 Million |
+13.36% |
| 2001-12-31 | CN¥130.09 Million ≈ $19.04 Million |
-- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more